Precision biochemistry via nextgen microflow control

The PRECIBIO pilot (“Precision biochemistry via next-gen microflow control”) brings together the Microfluidic Innovation Center (MIC) and Inside Therapeutics to unlock robust, industrial-grade microfluidic manufacturing for lipid nanoparticle (LNP)–based RNA and gene therapies. MIC, a deep-tech innovation center dedicated to turning advanced microfluidic technologies into industrial solutions for bioproduction and health, deploys its Galileo next-generation microfluidic flow-sensing technology to deliver accurate, real-time measurements even under fast, transient and pulsed-flow conditions where conventional sensors struggle. This Galileo- enabled precision gives Inside Therapeutics—a French biotech developing next-generation microfluidic platforms to bridge the gap between R&D and GMP- ready production—the process visibility and control needed to scale their LNP manufacturing while meeting stringent quality and regulatory requirements, ultimately accelerating the arrival of new RNA and gene-based therapies to patients.